All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

News

Article

July 1, 2015

DOJ Enters Consent Decree Against Acino Products

Author(s):

Pharmaceutical Technology Editors

US Court orders New Jersey drug manufacturer and its president to stop distribution of unapproved and misbranded drugs.

 

The US District Court for the District of New Jersey has entered a consent decree of permanent injunction against Acino Products LLC, of Hamilton, NJ, and its president, Ravi Deshpande, to prevent the distribution of unapproved and misbranded drugs, the Department of Justice (DOJ) announced in a press statement on July 1. 

The DOJ filed a complaint at the request of FDA alleging that the company’s hydrocortisone acetate suppositories-marketed under the brand names Rectacort-HC and GRx HiCort 25-are not approved by the FDA and that they are misbranded because they do not bear adequate directions for use as required by law. 

In conjunction with the filing of the complaint, the defendants agreed to settle the litigation and be bound by a consent decree of permanent injunction requires the drug manufacturer to cease all manufacture and distribution of the unapproved and misbranded suppositories, and to destroy any such suppositories already in existence.

The FDA has conducted at least three inspections of the facility between Feb. 6–March 5, 2014; Aug. 7–19, 2014; and Jan. 12–25, 2015.

According to the complaint, during the February/March 2014 inspection, FDA investigators documented the company’s manufacturing of hydrocortisone acetate suppositories on behalf of Ascend Laboratories LLC.  The complaint alleges that at the conclusion of the inspection, Deshpande indicated that he was aware that the suppositories were being marketed by Ascend as prescription drugs without FDA approval.    

In May 2014, the government conducted a seizure of certain unapproved and misbranded drugs that were being distributed by Ascend, including suppositories that Acino had manufactured for Ascend.  The government notified Acino and Deshpande of the seizure by a letter dated May 15, 2014.  According to the complaint, the letter made clear that the suppositories were unapproved and misbranded drugs, however, Acino and Deshpande continued to manufacture the products. 

According to the complaint, at the conclusion of the August 2014 and January 2015 inspections, FDA investigators again discussed the unapproved status of the hydrocortisone acetate 25-mg suppositories with Deshpande, who indicated that he was aware of the need to pursue FDA approval for the drug.  As alleged in the complaint, to date, Acino and Deshpande have not filed the necessary application with the FDA to gain approval for the unapproved drug products, DOJ reports in the press statement.

Source: US Department of Justice

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Related Content
Advertisement
High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com
August 6th 2025

The Future of Pharma: Connected, Continuous, and Compliant

Mike Hennessy Jr.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 6th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
gemstones using infrared spectroscopy | Image Credit: © poco_bw - stock.adobe.com
August 6th 2025

FDA Adopts Intact NMR to Advance Nanoemulsion Drug Quality Assessment

Patrick Lavery
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 6th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Chemical molecular formula hormone serotonin. Silhouette of a man head. Connected lines with dots background. | Image Credit: © JEGAS RA - stock.adobe.com
August 6th 2025

Zenara Secures First Generic Sertraline Approval from FDA, Plus Six Months of Market Exclusivity

Patrick Lavery
Futuristic health tech. A smartwatch projects a holographic health dashboard, providing real-time body analytics and vital signs monitoring anytime, anywhere. | Image Credit: © woravut - stock.adobe.com
August 6th 2025

How FDA’s ISTAND Initiative Supports Innovative Tools in Drug Discovery and Development

Patrick Lavery
Related Content
Advertisement
High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com
August 6th 2025

The Future of Pharma: Connected, Continuous, and Compliant

Mike Hennessy Jr.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 6th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
gemstones using infrared spectroscopy | Image Credit: © poco_bw - stock.adobe.com
August 6th 2025

FDA Adopts Intact NMR to Advance Nanoemulsion Drug Quality Assessment

Patrick Lavery
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 6th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Chemical molecular formula hormone serotonin. Silhouette of a man head. Connected lines with dots background. | Image Credit: © JEGAS RA - stock.adobe.com
August 6th 2025

Zenara Secures First Generic Sertraline Approval from FDA, Plus Six Months of Market Exclusivity

Patrick Lavery
Futuristic health tech. A smartwatch projects a holographic health dashboard, providing real-time body analytics and vital signs monitoring anytime, anywhere. | Image Credit: © woravut - stock.adobe.com
August 6th 2025

How FDA’s ISTAND Initiative Supports Innovative Tools in Drug Discovery and Development

Patrick Lavery
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.